Next Article in Journal
Is Silver the Ultimate Antimicrobial Bullet?
Next Article in Special Issue
Interventions to Reduce Antibiotic Prescribing in LMICs: A Scoping Review of Evidence from Human and Animal Health Systems
Previous Article in Journal
Biocidal Agents Used for Disinfection Can Enhance Antibiotic Resistance in Gram-Negative Species
Previous Article in Special Issue
Cost-Effectiveness Analysis of the Use of Point-of-Care C-Reactive Protein Testing to Reduce Antibiotic Prescribing in Primary Care
Open AccessConcept Paper

Combatting Antibiotic Resistance Together: How Can We Enlist the Help of Industry?

1
Department of Health Care Management, Berlin University of Technology, Straße des 17. Juni 135, 10623 Berlin, Germany
2
Infection Control Programme, WHO Collaborating Centre, University of Geneva Hospitals and Faculty of Medicine, Rue Gabrielle-Perret-Gentil 4, 1205 Geneva, Switzerland
3
LSE Health, London School of Economics and Political Science, Houghton Street, London WC2A 2AE, UK
*
Author to whom correspondence should be addressed.
Antibiotics 2018, 7(4), 111; https://doi.org/10.3390/antibiotics7040111
Received: 15 November 2018 / Revised: 11 December 2018 / Accepted: 13 December 2018 / Published: 18 December 2018
The development of antibiotics needs to be supported through new financial stimuli, including help from the public sector. In exchange for public support, industry should be asked to do what is in their power to help curb the inappropriate use of antibiotics. This work discusses key areas through which industry has an important influence on antibiotic consumption and where agreements can be made alongside financial incentives, even those intended to stimulate very early research. As long as the traditional unit sale-based business model for antibiotics remains in place, profit-making incentives will likely undermine efforts to sell and utilize antibiotics in a sustainable manner. In the short-term, while we try to come to a consensus on how best to fix the market, we need measures to prevent major over-selling and inappropriate promotion—especially for new, badly needed antibiotics that reach the market. This paper explores ways in which the pharmaceutical industry could help buttress sustainable antibiotic use while we search for more long-term, constructive, mutually-beneficial ways to organize the market. View Full-Text
Keywords: antibiotics; antimicrobial resistance; antibiotic consumption; marketing; promotion; pharmaceutical industry; research and development incentives; health economics; sustainable use antibiotics; antimicrobial resistance; antibiotic consumption; marketing; promotion; pharmaceutical industry; research and development incentives; health economics; sustainable use
Show Figures

Figure 1

MDPI and ACS Style

Edwards, S.E.; Morel, C.M.; Busse, R.; Harbarth, S. Combatting Antibiotic Resistance Together: How Can We Enlist the Help of Industry? Antibiotics 2018, 7, 111. https://doi.org/10.3390/antibiotics7040111

AMA Style

Edwards SE, Morel CM, Busse R, Harbarth S. Combatting Antibiotic Resistance Together: How Can We Enlist the Help of Industry? Antibiotics. 2018; 7(4):111. https://doi.org/10.3390/antibiotics7040111

Chicago/Turabian Style

Edwards, Suzanne E.; Morel, Chantal M.; Busse, Reinhard; Harbarth, Stephan. 2018. "Combatting Antibiotic Resistance Together: How Can We Enlist the Help of Industry?" Antibiotics 7, no. 4: 111. https://doi.org/10.3390/antibiotics7040111

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop